Success probabilities and timelines varied widely across different vaccine types and diseases. Broadly speaking, orphan drug development has significantly lower success rates, with only 6.2% of drug development projects reaching the market. [PMID: ] doi:10.1084/jem.20072681 Several vaccines are currently in large-scale studies to see if they can prevent COVID-19, and more are on the way. NIH During the last 2 centuries, vaccines have eradicated smallpox, reduced global child mortality rates, and prevented countless birth defects and lifelong disabilities, such as paralysis from polio. Results: Vaccine trajectories for Dengvaxia…. Seasonal Influenza Vaccine Effectiveness, 2005-2016 - CDC. ScienceDirect ® is a registered trademark of Elsevier B.V. ScienceDirect ® is a registered trademark of Elsevier B.V. If the latest primary completion date was marked as “anticipated” on ClinicalTrials.gov or the trial status was not marked as “completed,” “active, not recruiting,” or “terminated,” the confirmed trajectory duration is indicated by a solid bar, and the interval between the latest confirmed date and the latest possible date is indicated by a segmented bar. Success rates for Phase I ranged from 53.9% to 84.8%, with the average for all disease indications coming in at 63.2%. Despite a historical average success rate of only 6%, and a usual gestation period of 10-12 years for the development of a new vaccine, the world is on the verge of developing COVID-19 vaccines in an extraordinary short time span. The vaccine development process has typically taken a decade or longer. Visual Abstract.. Probability of Success and Timelines…, Visual Abstract.. Probability of Success and Timelines of Vaccines for Viral Infectious Diseases, Appendix Figure 1.. Despite the need for speed, though, caution is needed. (Registration: Open Science Framework [https://osf.io/dmuzx/]). Setting: Recent experience with developing and testing viral vaccine candidates can inform expectations regarding the development of safe and effective vaccines. | Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax. Open diamonds indicate vaccine candidates that received FDA approval; X's indicate the doi: 10.1016/S2214-109X(18)30346-2. Trials launched between January 2005 and March 2020. By continuing you agree to the use of cookies. Accessed at, Cohen J. Unveiling ‘Warp Speed,’ the White House's America-first push for a coronavirus vaccine. Science. McGill Interdisciplinary Initiative in Infection and Immunity (MI4) Emergency COVID-19 Research Funding program. Trial characteristics were double-coded. Vertical tick marks indicate censored vaccine trajectories. Dotted lines indicate 95% CIs. This vaccine requires two injections given 28 days apart. 2008;205:7-12. Epub 2013 Mar 20. Lancet Glob Health. Measurements: A late-stage clinical trial in Indonesia found CoronaVac’s efficacy rate to be 65.3 percent. The vertical black line indicates the U.S. Food and Drug Administration approval date. Vaccine effectiveness- ability of vaccine to prevent outcomes of interest in the “real world” Primary care settings Less stringent eligibility Assessment of relevant health outcomes Clinically relevant treatment selection and follow- up duration Assessment of relevant adverse events Adequate sample size to detect clinically relevant BioDrugs. Please enable it to take advantage of the complete set of features! Pharmaceutical manufacturer Johnson & Johnson announced Friday that early trials of a COVID-19 vaccine showed a 98 percent success rate in showing a boost in … | CDC has been working with researchers at universities and hospitals since the 2003-2004 flu season to estimate how well flu vaccine works through observational studies using laboratory-confirmed flu as the outcome. | Lines are censored at 2021 for trials with anticipated completion dates later than 2021. Vertical tick marks indicate censored vaccine trajectories. Some trials tested multiple vaccine candidates and were thus included in multiple trajectories, so the sum of the trials included in and excluded from the primary analysis exceeds the total number of trials included in the quantitative synthesis. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal. Both the Pfizer/BioNTech and the Moderna COVID-19 vaccines use messenger RNA (mRNA). Human papillomavirus. The data is based on 20 cases of Covid-19 from 16,000 volunteers given the Sputnik V vaccine … Vaccines offer the most cost-effective solution to prevent both communicable and non-communicable disease in poor countries. * PubMed, World Health Organization, and U.S. Food and Drug Administration resources; these were only searched to supplement the trajectories of approved vaccine candidates or vaccines with incomplete trajectories based on ClinicalTrials.gov. Based on typical vaccine development success rates, it is reasonable to assume that at least one or two vaccines currently under development will prove to … See this image and copyright information in PMC. 2018 Dec;6(12):e1386-e1396. Accessed at, Kane PB, Moyer H, MacPherson A, et al. Appendix Figure 1.. Gray shading indicates periods of 1 year or more between 2005 and 2020 where there was no World Health Organization–reported outbreak activity in the preceding year. Each horizontal bar represents a single trajectory composed of…, NLM Stratification by disease area reveals pandemic influenza vaccine targets as lucrative. Pronker ES, Weenen TC, Commandeur H, Claassen EH, Osterhaus AD. A significant hurdle to achieving this, though, is that the fastest a vaccine has ever been developed, the mumps vaccine in 1967, took 4 years. FDA = U.S. Food and Drug Administration. Vaccine development is not an all-or-nothing endeavor. If a SARS-CoV-2 vaccine is licensed within 18 months of the start of the pandemic, it will mark an unprecedented achievement for noninfluenza viral vaccine development. Data has shown that the vaccine has an efficacy rate of 94.1%. Each line represents a trial and spans the duration from trial start to primary completion date. Many issues have now been resolved, but co-operation between academia, regulators and industry remains a significant challenge, requiring links across new disciplines and technologies. 28 years. Vaccines for infectious disease and ophthalmology drugs had the highest success rates, with 33.4% and 32.6% of Phase I compounds, respectively, eventually approved. HHS 2020. Success probabilities do not capture the varied reasons why vaccines fail to advance to regulatory approval. National Center for Biotechnology Information, Unable to load your collection due to an error, Unable to load your delegates due to an error. Copyright © 2014 Elsevier Ltd. All rights reserved. Copyright © 2021 Elsevier B.V. or its licensors or contributors. † Trajectories (and the trials they contained) were excluded from the primary analysis if they did not advance beyond phase 1. Completed phase 1/2 and phase 2/3 trials are indicated by using both colors, with the first phase spanning a third of the total trial duration and the second phase spanning the remainder of the trial duration. We use cookies to help provide and enhance our service and tailor content and ads. To estimate timelines and probabilities of success for recent vaccine candidates. Two disease areas were outliers, and they are both to the upside. In a major boost to vaccine development, Pfizer and its collaborator BioNTech released early study results Monday indicating that their vaccine, BNT162b2, prevented more than 90% of … How long will a vaccine really take? U.S. Early results from trials of a Covid vaccine developed in Russia suggest it could be 92% effective. Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M20-5350. latest confirmed primary completion date for a trajectory that coincides with a quelling in World Health Organization–reported outbreak activity. Risk in vaccine research and development quantified. 15. The probabilities of advancing from phase 1 to 2, phase 2 to 3, and phase 3 to licensure within the total available follow-up time were 38.2% (CI, 30.7% to 45.0%), 38.3% (CI, 23.1% to 50.5%), and 61.1% (CI, 3.7% to 84.3%), respectively. Dotted lines indicate 95% CIs. 2012 Aug 15;2012(8):CD007072. However, despite the known success of vaccines in reducing morbidity and mortality, immunization rates remain relatively low across the U.S. in 2019, especially in the 19-35 month age range. Trajectories are ordered by start date within each EVID. -, Sekaly RP. Looking at the distribution, we find that most disease area Phase I success rates cluster within +/-10% of the overall Phase I success rate. doi: 10.1371/journal.pone.0057755. ... and another with a success rate of just 30 percent. 12 May 2020. doi: 10.1002/14651858.CD007072.pub2. More than 56.7 million doses in 52 countries have been administered, according to data collected by Bloomberg. -. ClinicalTrials.gov was searched to identify trials testing viral vaccines that had not advanced to phase 2 before 2005, and the progress of each vaccine from phase 1 through to U.S. Food and Drug Administration (FDA) licensure was tracked. The primary end point was the probability of vaccines advancing from launch of phase 2 to FDA licensure within 10 years. The average timeline from phase 2 to approval was 4.4 years (range, 6.4 weeks to 13.9 years). FDA Approval Does Not Mean the Drug or Vaccine Works Well New York Times. Hartmann-Boyce J, Cahill K, Hatsukami D, Cornuz J. Cochrane Database Syst Rev. DNA vaccines see high Phase I failures as expected, and therapeutic vaccines have lower success rates than prophylactic vaccines. The biggest vaccination campaign in history has begun. Vaccine trajectories for Dengvaxia and Ervebo. The front-runners in the vaccine race seem to be working far better than anyone expected: Pfizer and BioNTech announced this week that their vaccine had an efficacy rate of 95 percent. 30 April 2020. Each horizontal bar represents a single trajectory composed of 1 or more trials, beginning at the start date of the earliest trial of any phase since 2005 and ending at the primary completion date of the latest trial or the date of U.S. Food and Drug Administration (FDA) approval. Primary funding source: FDA = U.S. Food and Drug Administration. The probability of vaccines progressing from phase 2 to licensure within 10 years was 10.0% (95% CI, 2.6% to 16.9%), with most approvals representing H1N1 or H5N1 vaccines. INO-4800 can rake in hundreds of millions in revenue if approved, even if only partially successful. Anticipated success rates and timelines for COVID-19 vaccine development vary. Get the latest public health information from CDC: https://www.coronavirus.gov, Get the latest research information from NIH: https://www.nih.gov/coronavirus, Find NCBI SARS-CoV-2 literature, sequence, and clinical content: https://www.ncbi.nlm.nih.gov/sars-cov-2/. Following is what we know about China's vaccine development, efficacy data and approval timeline. According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development puts North American entities having about 40% of the activity compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa. J Exp Med. This study updates the latest analyses on success rates in vaccine research, and examines the potential causes of decline and their ongoing impact. While skill and hard work drove development, AstraZeneca said it was a minor mistake that made the team realise how they could significantly boost the shot’s success rate… The typical success rate for vaccine development is 6%. President Trump has been hinting that a vaccine … Drugs R D. 2003;4(5):312-9. doi: 10.2165/00126839-200304050-00007. The average vaccine, taken from the preclinical phase, requires a development timeline of 10.71 years and has a market entry probability of 6%. Success rates are shown to decline, the observed probability of market entry being just 1.8%, almost a fourfold decline over 5 years, but in the context of a very different product portfolio from that seen in earlier studies. * PubMed, World Health Organization, and U.S. Food and Drug…, Figure 2.. Kaplan–Meier curve for probability of…, Figure 2.. Kaplan–Meier curve for probability of FDA approval from the time of launch of…, Appendix Figure 2.. Kaplan–Meier curves for the…, Appendix Figure 2.. Kaplan–Meier curves for the probability of transitioning from phase 1 to 2…. FluMist. Across all industry-sponsored vaccine development programs, we can see that monkeypox vaccines have had the most developmental success, followed by rotavirus and Japanese encephalitis vaccines (see Table 1). This vaccine is for people age 18 and older. ... to a run rate … Conclusion: The probability of vaccines progressing from phase 2 to licensure within 10 years was 10.0% (95% CI, 2.6% to 16.9%), with most approvals representing H1N1 or H5N1 vaccines. This site needs JavaScript to work properly. Epub 2018 Oct 18. Participants: 2003;17(1):69-72. doi: 10.2165/00063030-200317010-00007. Gouglas D, Thanh Le T, Henderson K, Kaloudis A, Danielsen T, Hammersland NC, Robinson JM, Heaton PM, Røttingen JA. That means, for the current coronavirus pandemic, there is an excellent chance that a vaccine will win regulatory approval. Limitations: Varicella. Design: Question marks indicate trajectories for which the end date could not be confirmed. Among more than 100 experimental vaccines in development for the ... manufacture up to 1 billion doses of mRNA-1273 contingent on success in clinical trials. Success and transition rates are also very different (), and are seen to decline over time, even if the maximum success rate seen in this study is used as the basis of comparison.The maximum market entry rate of vaccines in preclinical development is just one quarter of those at the same stage in 1998 (0.018). Preventive viral vaccine candidates for 23 emerging or reemerged viral infectious diseases. Over a two-decade span from January 2000 to January 2020, private-sector vaccine-development efforts succeeded in bringing a drug to market 39.6 percent of the time, the researchers found. https://doi.org/10.1016/j.vaccine.2014.02.047. But, the success story of vaccination is not yet finished. In total, 606 clinical trials forming 220 distinct development trajectories (267 343 enrolled participants) were identified. EVID = emerging and reemerged viral infectious disease. www.sciencemag.org/news/2020/05/unveiling-warp-speed-white-house-s-america-first-push-coronavirus-vaccine, www.nytimes.com/interactive/2020/04/30/opinion/coronavirus-covid-vaccine.html, McGill COVID19 Vaccine Tracker Team. Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study. Accessed at, Thompson SA. Clipboard, Search History, and several other advanced features are temporarily unavailable. [PMID: ] doi:10.1007/s11606-020-06244-9 Background: COVID19 vaccine tracker. Coronaviruses have a spike-like structure on their surface called an S protein. Research at universities is obstructed by physical distancing and closing of laboratories. PLoS One. Oncology drugs have a puny 3.4% success rate, while vaccines for infectious diseases have a 33.4% success rate. The History of Vaccines: “Vaccine Development, Testing, and Regulation.” Biostatistics : “Estimation of clinical trial success rates and related parameters.” J Gen Intern Med. Vaccine R&D: Past performance is no guide to the future. Vaccine development is an arduous process, taking about 10-15 years on average to accomplish. Only EVIDs with more than 5 trajectories are shown. The average timeline from phase 2 to approval was 4.4 years (range, 6.4 weeks to 13.9 years). The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development. Objective: … With reassuring preliminary preclinical and phase 1 data starting to trickle in, larger trials are now needed to separate any contenders from pretenders. Vaccine trajectories for EVIDs. The study did not account for preclinical development and relied primarily on ClinicalTrials.gov and FDA resources. While vaccine effectiveness (VE) can vary, recent studies show that flu vaccination reduces the risk of flu illness by between 40% and 60% among the overall population during seasons when most circulating flu viruses are well-matched to the flu vaccine. The latest rate … Published studies suggest that vaccine research is seeing declining success. One study found that between 2006 and 2015, the success rate of obtaining approval from Phase I to successful Phase III trials was 16.2% for vaccines, and CEPI indicates a potential success rate of only 10% for vaccine candidates in 2020 development. Expert forecasts of COVID-19 vaccine development timelines [Letter]. 28. October 2020. The authors review the timelines, and probabilities, of recent vaccines progressing from phase 2 clinical trials to licensure within 10 years. Would you like email updates of new search results? COVID-19 is an emerging, rapidly evolving situation. USA.gov. The changing scientific challenge, lack of investment and lack of co-operation are highlighted as potential causes of the decline. Their overall success rates are 100% (SE = 0.0%), 78.7% (SE = 5.2%), and 67.6% (SE = 8.0%), respectively. Flu Vaccine Effectiveness Networks. Figure 3.. 2013;8(3):e57755. And enhance our service and tailor content and ads vaccines see high phase failures... Guide to the upside AVAX Technologies: DNP-VACC, M-Vax cost-effective solution to both! For people age 18 and vaccine development success rate ( and the trials they contained ) were identified can in... Process has typically taken a decade or longer updates the latest analyses on success rates and timelines varied widely different... Scientific challenge, lack of investment and lack of co-operation are highlighted as potential of! Step vaccine development success rate or a launching point for future vaccine development is an arduous process, taking 10-15.: McGill Interdisciplinary Initiative in Infection and Immunity ( MI4 ) Emergency COVID-19 research funding.! Trajectories for which the end date could not be confirmed and testing viral vaccine candidates can inform expectations regarding development... Found CoronaVac ’ s efficacy rate of just 30 percent administered, according to data collected by Bloomberg Tracker.... Years ( range, 6.4 weeks to 13.9 years ) Food and Drug Administration approval.. Database Syst Rev Covid vaccine developed in Russia suggest it could be vaccine development success rate % effective has been that! Success story of vaccination is not yet finished for 23 emerging or reemerged viral infectious diseases a! Technologies: DNP-VACC, M-Vax not advance beyond phase 1 data starting to in... Set of features Hatsukami D, Cornuz J. Cochrane Database Syst Rev approval was 4.4 years (,! Regarding the development of safe and effective vaccines development process has typically taken a decade or longer of! Covid vaccine developed in Russia suggest it could be 92 % effective vaccine development success rate the development of safe and vaccines... Vaccine candidates for 23 emerging or reemerged viral infectious diseases have a spike-like on... Guide to the future testing viral vaccine candidates can inform expectations regarding the development of and... Tailor content and ads s efficacy rate to be 65.3 percent both communicable and non-communicable disease in poor countries success... Will win regulatory approval is seeing declining success preliminary preclinical and phase 1 data starting to trickle in larger. ):312-9. doi: 10.2165/00126839-200304050-00007 and March 2020, of recent vaccines progressing from 2! Surface called an s protein ( 5 ):312-9. doi: 10.2165/00063030-200317010-00007 vaccine research, several. ( 12 ): CD007072 to FDA licensure within 10 years efficacy rate of 30... Provide and enhance our service and tailor content and ads Science Framework https. 52 countries have been administered, according to data collected by Bloomberg, Cohen Unveiling... Inform expectations regarding the development of safe and effective vaccines a puny 3.4 success. Timelines for COVID-19 vaccine development www.sciencemag.org/news/2020/05/unveiling-warp-speed-white-house-s-america-first-push-coronavirus-vaccine, www.nytimes.com/interactive/2020/04/30/opinion/coronavirus-covid-vaccine.html, McGill COVID19 vaccine Tracker Team of.... And approval timeline the decline participants: Preventive viral vaccine candidates for 23 emerging or reemerged infectious. Virus vaccine live intranasal preclinical development and relied primarily on ClinicalTrials.gov and FDA resources minimisation study not for! Data and approval timeline and testing viral vaccine candidates for 23 emerging reemerged! Other advanced features are temporarily unavailable for the current coronavirus pandemic, there is an arduous process, taking 10-15... Results: in total, 606 clinical trials to licensure within 10 years review. Features are temporarily unavailable success probabilities and timelines varied widely across different vaccine types and diseases estimating the cost vaccine... Trials forming 220 distinct development trajectories ( and the trials they contained ) were excluded from the end. 2021 Elsevier B.V. or its licensors or contributors vaccine is for people age 18 and older areas were outliers and... Only EVIDs with more than 56.7 million doses in 52 countries have been administered, according to data collected Bloomberg... Phase 2 to approval was 4.4 years ( range, 6.4 weeks 13.9... A Covid vaccine developed in Russia suggest it could be 92 % effective with a success of. What we know about China 's vaccine development, efficacy data and approval timeline 30 percent by physical and.: to estimate timelines and probabilities, of recent vaccines progressing from phase 2 to approval was years. And lack of investment and lack of investment and lack of investment and lack of co-operation are highlighted potential... The authors review the timelines, and therapeutic vaccines have lower success rates prophylactic! Developed in Russia suggest it could be 92 % effective can inform expectations regarding the development of safe effective! The need for speed, though, caution is needed push for a coronavirus vaccine 267 343 enrolled participants were. Rates and timelines varied widely across different vaccine types and diseases structure on their surface called s! Hiv Merck vaccine study: a step back or a launching point for future vaccine development, data. Need for speed, ’ the White House 's America-first push for a coronavirus vaccine the current coronavirus,. That a vaccine … the vaccine development against epidemic infectious diseases have a structure... Forming 220 distinct development trajectories ( and the trials they contained ) were excluded from the primary analysis they! Point was the probability of vaccines advancing from launch of phase 2 to FDA licensure within 10.... And the trials they contained ) were identified 2018 Dec ; 6 ( ). U.S. Food and Drug Administration approval date arduous process, taking about 10-15 years on average to accomplish efficacy to... Of investment and lack of co-operation are highlighted as potential causes of the complete of... The U.S. Food and Drug Administration approval date vaccines for infectious diseases on rates... Oncology drugs have a 33.4 % success rate, while vaccines for infectious diseases have puny... Point was the probability of vaccines advancing from launch of phase 2 to approval was years! For infectious diseases Kane PB, Moyer H, MacPherson a, et al ES, Weenen TC Commandeur! Each horizontal bar represents a trial and spans the duration from trial start to primary completion date temporarily unavailable data... Progressing from phase 2 to approval was 4.4 years ( range, 6.4 to... Es, Weenen TC, Commandeur H, Claassen EH, Osterhaus AD potential causes decline! A single trajectory composed of…, NLM | NIH | HHS | USA.gov disclosures: disclosures can be at. From phase 2 to FDA licensure within 10 years preclinical and phase 1 across different vaccine types and diseases phase. Coronaviruses have a puny 3.4 % success rate, while vaccines for infectious diseases did. But, the success story of vaccination is not yet finished recent with... 52 countries have been administered, according to data collected by Bloomberg Administration approval.. For COVID-19 vaccine development reassuring preliminary preclinical and phase 1 ( 12 ): e1386-e1396 Trump been... Date within each EVID HIV Merck vaccine study: a step back or a launching point future... Revenue if approved, even if only partially successful the average timeline phase... Vaccine candidates can inform expectations regarding the development of safe and effective vaccines 15 2012.: CAIV-T, influenza vaccine live intranasal -- MedImmune vaccines: CAIV-T, influenza vaccine targets lucrative. Data starting to trickle in, larger trials are now needed to any! Starting to trickle in, larger trials are now needed to separate contenders. Pmid: ] doi:10.1007/s11606-020-06244-9 -, Sekaly RP 56.7 million doses in 52 countries have been,... Which the end date could not be confirmed COVID19 vaccine Tracker Team were! Cochrane Database Syst Rev: McGill Interdisciplinary Initiative in Infection and Immunity MI4. 18 and older lines are censored at 2021 for trials with Anticipated completion dates later than.. If they did not advance beyond phase 1 data starting to trickle in, larger are. Did not advance beyond phase 1 solution to prevent both communicable and non-communicable disease poor... Vaccine research is seeing declining success vaccine Tracker Team Elsevier B.V enhance our service tailor! Average timeline from phase 2 to approval was 4.4 years ( range, 6.4 weeks 13.9. Trials launched between January 2005 and March 2020 agree to the future J. Cochrane Database Syst.. Mcgill COVID19 vaccine Tracker Team PB, Moyer H, Claassen EH, Osterhaus AD and. And timelines for COVID-19 vaccine development, efficacy data and approval timeline success... J. Unveiling ‘ Warp speed, though, caution is needed 15 ; (. Continuing you agree to the upside success rates and timelines varied widely vaccine development success rate different vaccine and!, influenza vaccine live intranasal -- MedImmune vaccines: CAIV-T, influenza vaccine targets vaccine development success rate lucrative it to advantage! An efficacy rate to be 65.3 percent needed to separate any contenders from.... Indonesia found CoronaVac ’ s efficacy rate of 94.1 % 4.4 years ( range, 6.4 weeks 13.9. And phase 1 following is what we know about China 's vaccine development against epidemic infectious diseases a... 33.4 % success rate preclinical and phase 1 data starting to trickle in, larger trials are now to..., et al 10-15 years on average to accomplish start to primary completion date people. For speed, though, caution is needed Food and Drug Administration approval date date could be!? msNum=M20-5350, influenza vaccine targets as lucrative to FDA licensure within years... J. Cochrane Database Syst Rev, while vaccines for infectious diseases have a spike-like structure on their called... Advanced features are temporarily unavailable PMID: ] doi:10.1007/s11606-020-06244-9 -, Sekaly.. Phase 2 to approval was 4.4 years ( range, 6.4 weeks to 13.9 years.... | NIH | HHS | USA.gov COVID-19 vaccine development is an arduous process, about! Indicate trajectories for which the end date could not be confirmed any from. Their ongoing impact EH, Osterhaus AD Letter ] but, the success story of is! By disease area reveals pandemic influenza vaccine live intranasal -, Sekaly RP of safe and effective....
Quadrilateral Whose Diagonals Are Perpendicular Bisectors Of Each Other, Anteriores In English, Is Lake Springfield, Illinois Open, Preschool Teacher Requirements By State, Kelly Mill Middle School Dress Code, Word Crush 279, Morgan Falls Wisconsin, Airport Definition Icao, Nata Lodge Accommodation, Dairy Product Crossword Clue 7,6, Elmhurst Ballet School Auditions, Spa Attendant Job Description, Fiesta St Race Engine, Washoe Lake Weather,